Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~Participants must meet all of the following criteria in order to be eligible to participate in the study:~* Male or female ≥1 year of age.~* Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year prior to randomization.~* Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3 consecutive laboratory values obtained on different days, and platelet count \>10,000/mm³ at the time of randomization.~* Diagnosed with HC based on the following criteria (all 3 criteria must be met):~  1. Clinical signs and/or symptoms of cystitis.~ 2. Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots.~ 3. Viruria with ≥1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6).~* At least 1 identified, suitably matched posoleucel (ALVR105) cell line for infusion is available.~Key Exclusion Criteria~Participants who meet any of the following criteria will be excluded from participation in the study:~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose \>0.5 mg/kg/day or equivalent).~* Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization.~* Evidence of active Grade \>2 acute graft versus host disease (GVHD).~* Uncontrolled or progressive bacterial or fungal infections.~* Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105).~* Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder.~* Known or presumed pneumonia secondary to any organism that is not considered to be well-controlled by antimicrobial therapy.~* Pregnant or lactating or planning to become pregnant.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
- Posoleucel (ALVR105) (Type: EXPERIMENTAL): Administered as 2-4 milliliter infusion, visually identical to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).